Gasser R W, Brandstetter G, Skrabal F
Wien Klin Wochenschr. 1982 Jan 8;94(1):25-8.
The optimal daily dose and dose regimen of a new drug combination (Pertenso), consisting of 10 mg bemetizide, 20 mg triamterene, 20 mg dihydralazine and 20 mg bupranolol were tested in 14 hypertensive outpatients (WHO I to III) in a single blind crossover trial. The mean blood pressure before treatment was 183/107 +/- 5/2 mm Hg (+/-SEM) and was lowered to a mean blood pressure of 147/89 +/- 4/4 mm Hg (+/- SEM; p less than 0,005) during a multiple dose regimen and to 141/84 +/- 3/3 mm Hg (+/- SEM; p less than 0,005) during a single dose regimen. The results indicate that even in hypertension which requires a combination of diuretics, vasodilators and beta-adrenergic blocking agents for treatment, a fixed combination of these substances could be given for effective blood pressure control. The data suggest the possibility of a single dose regimen of the fixed drug combination.
一种由10毫克苄氟噻嗪、20毫克氨苯蝶啶、20毫克双肼屈嗪和20毫克丁酰心安组成的新型复方药物（Pertenso），其最佳日剂量和给药方案在14例高血压门诊患者（WHO I至III级）中进行了单盲交叉试验。治疗前平均血压为183/107±5/2毫米汞柱（±标准误），在多剂量给药方案期间降至平均血压147/89±4/4毫米汞柱（±标准误；p<0.005），在单剂量给药方案期间降至141/84±3/3毫米汞柱（±标准误；p<0.005）。结果表明，即使在需要联合使用利尿剂、血管扩张剂和β-肾上腺素能阻滞剂进行治疗的高血压患者中，这些药物的固定组合也可有效控制血压。数据提示了固定复方药物单剂量给药方案的可能性。
